88 related articles for article (PubMed ID: 459012)
1. Long-term survival after hormonal therapy for stage D prostatic cancer.
Reiner WG; Scott WW; Eggleston JC; Walsh PC
J Urol; 1979 Aug; 122(2):183-4. PubMed ID: 459012
[TBL] [Abstract][Full Text] [Related]
2. [Factors influencing prognosis of stage D2 prostatic cancer following endocrine therapy: comparison between short-term cancer death and long-term survival group].
Masai M; Akimoto S; Isaka S; Shimazaki J; Yatani R
Hinyokika Kiyo; 1990 Jun; 36(6):667-71. PubMed ID: 1700585
[TBL] [Abstract][Full Text] [Related]
3. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
5. Analysis of factors influencing survival of 109 men with carcinoma of the prostate treated conservatively.
Hand JR
Trans Am Assoc Genitourin Surg; 1973; 65():84-99. PubMed ID: 4763516
[No Abstract] [Full Text] [Related]
6. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on prostatic cancer patients].
Yasumoto R; Asakawa M
Hinyokika Kiyo; 1989 Jan; 35(1):65-9. PubMed ID: 2729021
[TBL] [Abstract][Full Text] [Related]
10. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
11. Osteoblastic response to successful treatment of metastatic cancer of the prostate.
Pollen JJ; Shlaer WJ
AJR Am J Roentgenol; 1979 Jun; 132(6):927-31. PubMed ID: 108971
[TBL] [Abstract][Full Text] [Related]
12. Radiographic evaluation of treatment of advanced carcinoma of the prostate.
Kongtawng T; Sebes J; Ettman IK; Himmelfarb E
South Med J; 1978 Mar; 71(3):247-50. PubMed ID: 628849
[TBL] [Abstract][Full Text] [Related]
13. [Prostatic cancer between 50 and 60. A more than 20-year-long retrospective study. Apropos of 65 case reports].
Aubert J; Orget J; Bon D; Marroncle M
Acta Urol Belg; 1993 Dec; 61(4):5-12. PubMed ID: 7507634
[TBL] [Abstract][Full Text] [Related]
14. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
15. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
16. [Present status and questions on early prostatic cancer (stage A, B)].
Oishi K; Arai Y; Takeuchi H; Yoshida O
Hinyokika Kiyo; 1991 Aug; 37(8):789-93. PubMed ID: 1957722
[TBL] [Abstract][Full Text] [Related]
17. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
18. Survival following orchiectomy for stage D adenocarcinoma of the prostate.
Forrest JB; Howards SS
J Surg Oncol; 1984 Jan; 25(1):71-2. PubMed ID: 6694397
[TBL] [Abstract][Full Text] [Related]
19. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of metastatic prostate cancer: certainty and doubts].
Fournier G; Valéri A
Presse Med; 1998 Dec; 27(38):1996-2002. PubMed ID: 9879324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
